Abstracts Archive - Page 341 of 2607 - ACR Meeting Abstracts

Abstract Number: 0446 • ACR Convergence 2024
Rheum for Improvement: Contraception Counseling and Adherence in Patients with Lupus and Rheumatoid Arthritis on Teratogenic Medications
Kathryn Kompa¹ and Vasileios Kyttaris², ¹Beth Israel Deaconess Medical Center, Boston, MA, ²BIDMC, Boston, MA
Background/Purpose: Methotrexate (MTX) and mycophenolate (MMF) are two common medications for both lupus (SLE) and rheumatoid arthritis (RA). Both medications are contraindicated in pregnancy, necessitating…
Abstract Number: 0416 • ACR Convergence 2024
Proteomic Signatures of Synovial Fluid in Different Subtypes of Juvenile Idiopathic Arthritis
narendra bagri¹, saumya srivastava², yogendra singh², Thirumurthy Velpandian², Ashish Upadhyay², venkatesan sampath kumar², Subhradip Karmakar² and sushil K Kabra², ¹All India Institute of Medical Sciences, New Delhi, Delhi, India, ²AIIMS New Delhi, new delhi, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is heterogenous group of inflammatory disorder with clinically distinct subtypes; polyarticular, oligoarticular systemic onset JIA (sJIA), and enthesitis-related arthritis (ERA).…
Abstract Number: 0472 • ACR Convergence 2024
Impaired Cardiac Function in Contemporary Rheumatoid Arthritis Patients: A Comparative Pilot Study with Cardiovascular Magnetic Resonance-derived Strain Analysis
Bas Dijkshoorn¹, Sreen Mohamed², Romy Hansildaar², Henk Everaars³, Geoffrey Mooij³, Luuk Hopman³, Paul Knaapen³, Lourens Robbers³ and Michael Nurmohamed⁴, ¹Amsterdam Rheumatology and immunology Center, Amsterdam, Netherlands, ²Amsterdam Rheumatology and Immunology center location Reade, Amsterdam, Netherlands, ³Department of Cardiology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands, Amsterdam, Netherlands, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands
Background/Purpose: Heart failure (HF) is an important, underdiagnosed comorbidity, with increased morbidity and mortality rates in rheumatoid arthritis (RA) patients. The risk of developing HF…
Abstract Number: 0479 • ACR Convergence 2024
Constructing and Using a Novel Nucleotide Transformer for Patients with Rheumatoid Arthritis
Shant Ayanian, Collin Osborne, Marc Blasi, Daniel Darveaux, Eric Klee and Elena Myasoedova, Mayo Clinic, Rochester, MN
Background/Purpose: Applying the methods of artificial intelligence (AI) to genomic data for clinical outcome prediction in rheumatoid arthritis (RA) is an area of growing research.…
Abstract Number: 0430 • ACR Convergence 2024
Clues from Early Gestational Mean Arterial Pressure in Predicting Preeclampsia Risk in Systemic Lupus Erythematosus (SLE)
Rashmi Dhital¹, Dilli Poudel² and Ukachi Emeruwa³, ¹UC San Diego, Brentwood, TN, ²Vanderbilt University, Nashville, TN, Brentwood, TN, ³UC San Diego, San Diego
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a known risk factor for chronic hypertension (cHTN) as well as preeclampsia. While the role of cHTN is known,…
Abstract Number: 0476 • ACR Convergence 2024
Baricitinib in Rheumatoid Arthritis – Interstitial Lung Disease. National Multicenter Study of 72 Patients
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesús Alejandro Valero Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, María Martín López⁶, Santos Castañeda⁷, Jesús Loarce⁸, César Antonio Egües Dubuc⁹, Natalia Mena Vázquez¹⁰, Carmen Carrasco-Cubero¹¹, Carolina Perez-Garcia¹², Juan M Blanco Madrigal¹³, Nuria Vegas Revenga¹⁴, Lorena Pérez Albadalejo¹⁵, Rafaela Ortega-Castro¹⁶, Desiree Palma¹⁷, Ana Fernández-Ortiz¹⁸, Maria López Lasanta¹⁹, Marta Garijo Bufort²⁰, Ivette Casafont-Sole²¹, Andrea García-Valle²², Maria Paz Martinez-Vidal²³, Bryan Josué Flores Robles²⁴, EVELIN CERVANTES PEREZ²⁵, Ignacio Brana Abascal²⁶, Sara María Rojas Herrera²⁷, Juan Camilo Sarmiento-Monroy²⁸, Virginia Ruiz-Esquide²⁹, JOSE RAMON LAMUA RIAZUELO³⁰, Uxue Astigarraga-Urquia³¹, Diego Ferrer³² and Ricardo Blanco-Alonso³³, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Zumarraga Hospital, Zumarraga, Spain, ⁴Hospital de Jeréz de la Frontera, Cadiz, Spain, ⁵CHU Ourense, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Ciudad de México, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁹Hospital Universitario de Donostia, Donostia, Pais Vasco, Spain, ¹⁰IBIMA, Málaga, Andalucia, Spain, ¹¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³BASURTO UNIVERSITY HOSPITAL, Bilbao, Spain, ¹⁴Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁵Hospital Universitario de Jaén, Jaén, Spain, ¹⁶Hospital Reina Sofía, Cordoba, Andalucia, Spain, ¹⁷Hospital Rafael Méndez, Lorca, Murcia, Spain, ¹⁸Hospital Universitario de Badajoz, Badajoz, Spain, ¹⁹Hospital Vall d�Hebron, Barcelona, Spain, ²⁰Hospital de Sagunto, Valencia, Spain, ²¹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²²Hospital General Río Carrión, Palencia, Spain, ²³Hospital San Juan de Alicante, Alicante, Spain, ²⁴Hospital San Pedro, Logroño, Spain, ²⁵Complejo Hospitalario Universitario de Pontevedra, Pontevedra, Galicia, Spain, ²⁶Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ²⁷Hospital de Mérida, Badajoz, Spain, ²⁸Hospital Clínic Barcelona, Barcelona, Spain, ²⁹Hospital Clinic de Barcelona, Barcelona, Spain, ³⁰Hospital Universitario del Henares, Madrid, Spain, ³¹Hospital Universitario de Navarra, Pamplona, Spain, ³²Division of Pneumology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³³Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extraarticular manifestation of rheumatoid arthritis (RA) that determines a worse prognosis, leading the cause of mortality in RA…
Abstract Number: 0441 • ACR Convergence 2024
A Qualitative Improvement Project to Incorporate the Mycophenolate Risk Evaluation and Mitigation Strategies in an Academic Lupus Clinic
Dahima Cintron¹, Jennifer Rogers², Rebecca Sadun¹, Mithu Maheswaranathan³, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber³ and Megan Clowse⁴, ¹Duke University, Durham, NC, ²Duke, Durham, NC, ³Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC
Background/Purpose: Mycophenolate Mofetil/Mycophenolic acid (MMF) is an immunosuppressant used to treat SLE. Due to the teratogenic effects of MMF, the FDA recommended universal risk evaluation…
Abstract Number: 0452 • ACR Convergence 2024
Reproductive Health Needs of Women with Rheumatic Disease: An EMR-Based Online Survey Study
Krista Topalsky¹, Lindsay Frumker², Muhammad Shamim³, Omer Pamuk⁴, Jacqueline Colucci⁵ and Marina Magrey⁶, ¹University Hospitals/ Case Western Reserve University, Shaker Heights, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals/ Case Western Reserve University, Cuyahoga Falls, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH, ⁵University Hospitals, Cleveland, OH, ⁶Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH
Background/Purpose: Reproductive-aged women are disproportionately affected by rheumatologic disorders, making family planning issues like contraception, pre-conception counseling, fertility, pregnancy complications, and postpartum care critical components…
Abstract Number: 0432 • ACR Convergence 2024
Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study
Marion couderc¹, celine lambert², sabrina hamroun³, denis gallot⁴, Nathalie Costedoat-chalumeau⁵, Laure Gossec⁶, Gaëlle Guettrot-Imbert⁷, Veronique LE GUERN⁷, Christophe Richez⁸, MArtin Soubrier⁹ and Anna Molto¹⁰, ¹CHU de Clermont-Ferrand, Clermont-Ferrand, ²chu clermont ferrand, clermont ferrand, France, ³Rheumatology Department - Cochin Hospital, Paris, France, ⁴Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, ⁵University Paris Cité, Paris, France, ⁶Sorbonne Université, Paris, France, ⁷Cochin Hospital, Paris, France, ⁸Université de Bordeaux, Bordeaux, France, ⁹Gabriel-Montpied Hospital, Clermont-ferrand, France, ¹⁰Groupe Hospitalier Cochin, AP-HP, Paris, France
Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
Abstract Number: 0459 • ACR Convergence 2024
Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo
Dovile Sinkeviciute¹, Sofie Falkenloeve Madsen², Nicolas Willumsen³, Patryk Drobinski³, Morten Karsdal³ and Anne-Christine Bay-Jensen³, ¹Nordic Bioscience, Herlev, Hovedstaden, Denmark, ²University of Copenhagen, Copenhagen N, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) pathogenesis involves a range of immune cells, for instance T-cells, neutrophils and macrophages. They produce proinflammatory factors, such as proteolytic enzymes,…
Abstract Number: 0474 • ACR Convergence 2024
Association Between Rheumatoid Arthritis and Survival After Cancer: A Systematic Literature Review and Meta-analysis
Joshua Hsieh¹, Avneet Kaur², Hemant Khandelia³, Teresa Jewell⁴, Aman Singh⁵, Lauren Barkley⁶, Ishan Bansal⁷, Simmi Oberoi⁸ and Namrata Singh⁹, ¹Lakeside High School, Seattle, WA, ²SUNY Upstate, Buffalo, NY, ³AIIMS, New Delhi, Delhi, India, ⁴University of Washington, Seattle, WA, ⁵Rajindra Hospital, Patiala, Punjab, India, ⁶Brandeis University, Boston, MA, ⁷Yale University, New Haven, CT, ⁸Rajindra Hospital, New Delhi, India, ⁹University of Washington, Bellevue, WA
Background/Purpose: Increasing evidence suggests that inflammation, a hallmark of rheumatoid arthritis (RA), is associated with an elevated risk of cancer and can influence cancer outcomes.…
Abstract Number: 0419 • ACR Convergence 2024
Placental Weights of Offspring Born to Women with Rheumatoid Arthritis and Juvenile Idiopathic Arthritis
Eugenia Chock¹, Zeyan Liew², Lars Henning Pedersen³ and Mette Oestergaard Thunbo³, ¹Yale School of Medicine, New Haven, CT, ²Yale Center for Perinatal, Pediatric and Environmental Epidemiology, New Haven, CT, ³Aarhus University, Aarhus, Denmark
Background/Purpose: Offspring of patients with chronic inflammatory arthritis have almost double the risk of being born small for gestational age. Placental insufficiency is one of…
Abstract Number: 0442 • ACR Convergence 2024
Anti-U1-RNP Related Pregnancy Loss in Systemic Lupus Erythematosus
Anam Nazir¹, Joshua Reed², Khalid Alghamdi² and Catherine Ivory¹, ¹The Ottawa Hospital, Ottawa, ON, Canada, ²The Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Systemic lupus erythematosus (SLE) affects women of childbearing years and confers an increased risk of pregnancy complications. Risk of adverse events in pregnancy is…
Abstract Number: 0455 • ACR Convergence 2024
Contraception Counseling for Patients with Rheumatic and Musculoskeletal Diseases (RMDs) at a Tertiary Care Rheumatology Clinic: A Quality Improvement Project
Ikwinder Preet Kaur¹, Gurjit Kaeley², Cristine Arcilla³, Ngun Par⁴ and Thway Myant⁵, ¹University of Florida College of Medicine, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL, ³University of Florida Jacksonville, Jacksonville, FL, ⁴University of Florida Jacksonville Physicians Inc, Jacksonville, ⁵UF Jacksonville, Mia, FL
Background/Purpose: RMD patients are at increased risk of adverse pregnancy outcomes either from the active disease itself or the use of immunosuppressants incompatible with pregnancy.…
Abstract Number: 0453 • ACR Convergence 2024
Risk of Active Disease Determines the Expert Opinion Use of Biologics in Pregnancy, but Less in Breastfeeding, and in Men Planning a Family
Andrea Pluma¹, Linda Rüegg², Sabrina Hamroun³, Axel Finckh⁴, Yvette Meissner⁵ and Frauke Foerger⁶, ¹Vall d'Hebron University Hospital, Barcelona, Spain, ²Inselspital, Bern University Hospital, Bern, Switzerland, ³Cochin University Hospital, Paris, Ile-de-France, France, ⁴Geneva University Hospital, Geneva, Switzerland, ⁵Deutsches Rheuma-Forschungszentrum, Berlin, Germany, ⁶University hospital Bern /Inselspital Bern, Bern, Switzerland
Background/Purpose: Counselling patients with rheumatic and musculoskeletal diseases (RMD) in the phase of reproduction, pregnancy and breastfeeding is a challenging task. The potential risk of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].